Greg is the President and Chief Executive Officer of Reneo Pharmaceuticals and serves as a member of the company’s Board of Directors. Greg brings to Reneo more than 25 years of biopharmaceutical industry experience in executive management, corporate and business development, operations, sales and marketing, and clinical development. He has been closely involved with several novel development programs resulting in multiple product approvals and successful commercial launches in the U.S. and Europe.
Prior to joining Reneo, Greg was Chief Executive Officer and a member of the Board of Directors of Novus Therapeutics (Nasdaq: NVUS), a clinical-stage pharmaceutical company he took public in 2017 and led through the transformational acquisition of Anelixis Therapeutics in 2020. Prior to Novus, Greg was Chief Business Officer of publicly traded Avanir Pharmaceuticals (AVNR), a commercial-stage pharmaceutical company, where he led corporate and business development as well as corporate operations through the $3.5 billion acquisition of the company by Otsuka Pharmaceuticals in 2015. From 1995 to 2006, Greg held multiple leadership roles at Intermune (acquired by Roche), Amgen, and Eli Lilly and Company.
Greg received his B.S. in biology from Purdue University and studied biochemistry and molecular biology at Indiana University School of Medicine.
Alejandro (Alex) Dorenbaum, M.D., is the Chief Medical Officer of Reneo Pharmaceuticals. Previously, he was Chief Medical Officer at Allakos, where he achieved proof-of-concept in clinical trials for novel therapeutic antibodies targeting inflammatory cells. He also served as Chief Medical Officer at Lumena Pharmaceuticals until its acquisition by Shire Pharmaceuticals. Prior to that, Alex worked at Genentech, where he was responsible for the respiratory programs for asthma and cystic fibrosis, and at BioMarin Pharmaceutical, where he conducted the clinical development of Kuvan. He began his career at Chiron Corporation, gaining broad expertise in several areas of drug development including biologics, small molecules and vaccines.
Alex received his M.D. from the National Autonomous University in Mexico City. He completed his residency in pediatrics at University of Texas Health Science Center and held a fellowship in allergy and immunology at Baylor College of Medicine. He maintains an active academic position as Clinical Professor in Pediatrics at Stanford University School of Medicine, where he specializes in allergy and immunology.
Ashley is the Chief Development Officer of Reneo Pharmaceuticals. Ashley brings more than 22 years of biopharmaceutical industry experience in drug and biologics development across multiple therapeutic indications including in rare orphan diseases. Previously, Ashley was the Chief Development Officer and Head of Global Regulatory Affairs at Esperion Therapeutics, where she successfully led the regulatory approvals of the company’s two lead cholesterol lowering products, Nexletol® and Nexlizet®, in major markets around the world. Prior to joining Esperion, Ashley was the Global Regulatory Lead at Amgen, overseeing the regulatory strategy and global filings for the Repatha® program, which led to the world’s first approval of a PCSK9 inhibitor for cholesterol lowering. Prior to Amgen, Ashley was the Vice President of Regulatory Affairs at Micromet (acquired by Amgen) where she led the Blincyto® rare disease oncology program. Ashley also held prior leadership roles at RevoGenex, MedImmune (acquired by AstraZeneca), and Abraxis BioScience.
Ashley earned a Juris Doctorate (J.D.) from the University of San Diego School of Law and a Bachelor of Science in biochemistry and cell biology, with a minor in philosophy (bioethics), from the University of California, San Diego.
Greg is the President and Chief Executive Officer of Reneo Pharmaceuticals and serves as a member of the company’s Board of Directors. Greg brings to Reneo more than 25 years of biopharmaceutical industry experience in executive management, corporate and business development, operations, sales and marketing, and clinical development. He has been closely involved with several novel development programs resulting in multiple product approvals and successful commercial launches in the U.S. and Europe.
Prior to joining Reneo, Greg was Chief Executive Officer and a member of the Board of Directors of Novus Therapeutics (Nasdaq: NVUS), a clinical-stage pharmaceutical company he took public in 2017 and led through the transformational acquisition of Anelixis Therapeutics in 2020. Prior to Novus, Greg was Chief Business Officer of publicly traded Avanir Pharmaceuticals (AVNR), a commercial-stage pharmaceutical company, where he led corporate and business development as well as corporate operations through the $3.5 billion acquisition of the company by Otsuka Pharmaceuticals in 2015. From 1995 to 2006, Greg held multiple leadership roles at Intermune (acquired by Roche), Amgen, and Eli Lilly and Company.
Greg received his B.S. in biology from Purdue University and studied biochemistry and molecular biology at Indiana University School of Medicine.
Alejandro (Alex) Dorenbaum, M.D., is the Chief Medical Officer of Reneo Pharmaceuticals. Previously, he was Chief Medical Officer at Allakos, where he achieved proof-of-concept in clinical trials for novel therapeutic antibodies targeting inflammatory cells. He also served as Chief Medical Officer at Lumena Pharmaceuticals until its acquisition by Shire Pharmaceuticals. Prior to that, Alex worked at Genentech, where he was responsible for the respiratory programs for asthma and cystic fibrosis, and at BioMarin Pharmaceutical, where he conducted the clinical development of Kuvan. He began his career at Chiron Corporation, gaining broad expertise in several areas of drug development including biologics, small molecules and vaccines.
Alex received his M.D. from the National Autonomous University in Mexico City. He completed his residency in pediatrics at University of Texas Health Science Center and held a fellowship in allergy and immunology at Baylor College of Medicine. He maintains an active academic position as Clinical Professor in Pediatrics at Stanford University School of Medicine, where he specializes in allergy and immunology.
Ashley is the Chief Development Officer of Reneo Pharmaceuticals. Ashley brings more than 22 years of biopharmaceutical industry experience in drug and biologics development across multiple therapeutic indications including in rare orphan diseases. Previously, Ashley was the Chief Development Officer and Head of Global Regulatory Affairs at Esperion Therapeutics, where she successfully led the regulatory approvals of the company’s two lead cholesterol lowering products, Nexletol® and Nexlizet®, in major markets around the world. Prior to joining Esperion, Ashley was the Global Regulatory Lead at Amgen, overseeing the regulatory strategy and global filings for the Repatha® program, which led to the world’s first approval of a PCSK9 inhibitor for cholesterol lowering. Prior to Amgen, Ashley was the Vice President of Regulatory Affairs at Micromet (acquired by Amgen) where she led the Blincyto® rare disease oncology program. Ashley also held prior leadership roles at RevoGenex, MedImmune (acquired by AstraZeneca), and Abraxis BioScience.
Ashley earned a Juris Doctorate (J.D.) from the University of San Diego School of Law and a Bachelor of Science in biochemistry and cell biology, with a minor in philosophy (bioethics), from the University of California, San Diego.
Michael is the Chief Operating Officer of Reneo Pharmaceuticals. Michael brings more than 20 years of biopharmaceutical industry experience in corporation operations, business administration, human resources, commercial operations and information technology. Prior to joining Reneo, Michael was Novus Therapeutics’ (now Eledon Pharmaceuticals) Vice President of Corporate Operations, where he oversaw the daily non-finance general and administrative operations.
Michael previously served as the Vice President of Corporate Operations at Otic Pharma Ltd (acquired by Tokai Pharmaceuticals) and the Executive Director of Sales Operations at Avanir Pharmaceuticals (acquired by Otsuka Pharmaceuticals.) Earlier in his career, he co-founded a technology consulting firm focused on bringing technology platforms and business automation to small and mid-market organizations.
Michael holds a Bachelor of Science in Business Administration from Franklin University.
Michael is the Chief Operating Officer of Reneo Pharmaceuticals. Michael brings more than 20 years of biopharmaceutical industry experience in corporation operations, business administration, human resources, commercial operations and information technology. Prior to joining Reneo, Michael was Novus Therapeutics’ (now Eledon Pharmaceuticals) Vice President of Corporate Operations, where he oversaw the daily non-finance general and administrative operations.
Michael previously served as the Vice President of Corporate Operations at Otic Pharma Ltd (acquired by Tokai Pharmaceuticals) and the Executive Director of Sales Operations at Avanir Pharmaceuticals (acquired by Otsuka Pharmaceuticals.) Earlier in his career, he co-founded a technology consulting firm focused on bringing technology platforms and business automation to small and mid-market organizations.
Michael holds a Bachelor of Science in Business Administration from Franklin University.
Wendy is the Chief Business Officer of Reneo Pharmaceuticals. Previously, Wendy served as Reneo’s Chief Development Officer and was the company’s founding Chief Operating Officer. Wendy brings more than 30 years of experience in drug development, venture capital, licensing, strategy and corporate development. Prior to joining Reneo, Wendy was interim Chief Operating Officer and board member of AmpliPhi Bioscience (now Armata Pharmaceuticals).
Wendy previously served on the investment team at ProQuest Investments and was president and CEO of Aires Pharmaceuticals, acquired by Mast Therapeutics. She also served as senior vice president of corporate development at Salmedix until its acquisition by Cephalon/Teva, and held executive roles at WomenFirst Healthcare, Selective Genetics and Cytel. Earlier in her career, she was assistant director of the Center for Devices and Radiological Health at the U.S. Food and Drug Administration. Wendy holds an M.B.A. from Loyola University, an M.S. in clinical microbiology from the Hahnemann Medical School and a B.S. in microbiology from the University of Maryland.
